Global Blood Therapeutics (GBT) Survey Implies Expectation of Lower Stroke Risk, Could Lead to Standard of Care - Wells Fargo
Tweet Send to a Friend
Wells Fargo analyst Jim Birchenough reiterated an Overweight rating and $133.00 price target on Global Blood Therapeutics (NASDAQ: GBT) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
